Reports
Sale
Global Cell Therapy Manufacturing Market Size, Share, Forecast: By Therapy Type: T-Cell Therapies, Dendritic Cell Therapies, Tumor Cell Therapies, Stem Cell Therapies, Others; By Technology; By Source of Cell; By Scale of Operation; By Applications; By End User; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Global Cell Therapy Manufacturing Market Outlook
The global cell therapy manufacturing market size was valued at USD 4.24 billion in 2023, driven by the increasing prevalence of chronic diseases and technological advancement in the cell therapies across the globe. The market size is anticipated to grow at a CAGR of 14.7% during the forecast period of 2024-2032 to achieve a value of USD 14.60 billion by 2032.
Cell Therapy: Introduction
The transplantation of human cells, which is performed to treat cells and tissues in the human body, is known as cell therapy. With the help of cell therapy, repairing and replacement of damaged cells and tissues is performed in the human body. In cell therapy, healthy cells are inserted into the body of a person whose body has unhealthy cells and tissues and are in need to be restored or replaced. A variety of diseases can be potentially treated using cell therapy, such as cancer, cardiovascular diseases, neurological disorders, autoimmune disorders, and genetic disorders.
Global Cell Therapy Manufacturing Market Analysis
The increasing advancements in stem-cell research is one of the key factors which are driving the growth of the market. With the help of these advancements, personalized cell therapies would soon become a reality, and some are already under process of development. Additionally, the presence of chimeric antigen receptor T-cell (CAR-T) cell therapy has gained significant popularity in the last few years. The increasing focus on the manufacturing and scalability of the processes is also anticipated to aid the cell therapy manufacturing market expansion. Closed system manufacturing and process optimization are now in focus due to the increasing commercialization of cell therapies.
Global Cell Therapy Manufacturing Market Segmentations
Market Breakup by Therapy Type
- T-Cell Therapies
- Dendritic Cell Therapies
- Tumour Cell Therapies
- Stem Cell Therapies
- Others
Market Breakup by Technology
- Somatic Cell Technology
- Cell Immortalization Technology
- Viral Vector Technology
- Genome Editing Technology
- Cell Plasticity Technology
- 3D Technology
- Others
Market Breakup by Source of Cell
- Autologous Cell
- Allogeneic Cell
Market Breakup by Scale of Operation
- Preclinical
- Clinical
- Commercial
Market Breakup by Applications
- Oncology
- Cardiovascular Diseases
- Orthopaedic Diseases
- Others
Market Breakup by End User
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Others
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Cell Therapy Manufacturing Market Overview
The increasing prevalence of chronic diseases and technological advancement in cell therapies is primarily driving the cell therapy manufacturing market growth. After undergoing multiple observations and commercial practices, the efficiency and accuracy of mesenchymal stem cells, along with induced pluripotent stem cells, has provided positive responses from healthcare professionals about it. Their belief is that it can perform extensive tissue repair and immunomodulation with efficiency.
Due to the positive feedback, the demand for these cell therapies has increased and is expected to have a steady growth in the future. The educational institutions and research organization, along with key players present in the market, are collaborating with each other to provide and use resources and put them to better use by collaborating. The academical knowledge is used in research and development, which is further used to manufacture better therapies. With the immense potential of cell therapies, the global cell therapy manufacturing market demand has been witnessing steady growth and is expected to grow significantly in the coming years as well.
Global Cell Therapy Manufacturing Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Novartis AG
- F.Hoffmann La Roche AG
- Gilead Sciences, Inc.
- Thermo Fischer Scientific, Inc.
- Catalent, Inc.
- JSR Life Sciences LLC (KBI Biopharma Inc)
- Waisman Center (Waisman Biomanufacturing)
- Cell and Gene Therapy Catapult
- Merck KGaA
- Lonza Group
- Oxford Biomedica Plc
- WuXi AppTec
- Charles River Laboratories International Inc.
- Institut Merieux (ABL Inc.)
- BioCentriq
- Centre for Commercialization of Regenerative Medicine (CCRM)
- Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
- Amgen Inc.
- Bluebird Bio Inc.
- Takeda Pharmaceutical Company Limited
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment: Therapy Type
|
| Breakup by Therapy Type |
|
| Breakup by Technology |
|
| Breakup by Source of Cell |
|
|
Breakup by Scale of Operation |
|
| Breakup by Applications |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Cell Therapy Manufacturing Market Overview
3.1 Global Cell Therapy Manufacturing Market Historical Value (2017-2023)
3.2 Global Cell Therapy Manufacturing Market Forecast Value (2024-2032)
4 Global Cell Therapy Manufacturing Market Landscape
4.1 Global Cell Therapy Manufacturing Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Cell Therapy Manufacturing Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Technology
4.2.3 Analysis by Applications
5 Global Cell Therapy Manufacturing Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Cell Therapy Manufacturing Market Segmentation
6.1 Global Cell Therapy Manufacturing Market by Therapy Type
6.1.1 Market Overview
6.1.2 T-Cell Therapies
6.1.3 Dendritic Cell Therapies
6.1.4 Tumor Cell Therapies
6.1.5 Stem Cell Therapies
6.1.6 Others
6.2 Global Cell Therapy Manufacturing Market by Technology
6.2.1 Market Overview
6.2.2 Somatic Cell Technology
6.2.3 Cell Immortalization Technology
6.2.4 Viral Vector Technology
6.2.5 Genome Editing Technology
6.2.6 Cell Plasticity Technology
6.2.7 3D Technology
6.2.8 Others
6.3 Global Cell Therapy Manufacturing Market by Source of Cell
6.3.1 Market Overview
6.3.2 Autologous Cell
6.3.3 Allogeneic Cell
6.4 Global Cell Therapy Manufacturing Market by Scale of Operation
6.4.1 Market Overview
6.4.2 Preclinical
6.4.3 Clinical
6.4.4 Commercial
6.5 Global Cell Therapy Manufacturing Market by Applications
6.5.1 Market Overview
6.5.2 Oncology
6.5.3 Cardiovascular Diseases
6.5.4 Orthopedic Diseases
6.5.5 Others
6.6 Global Cell Therapy Manufacturing Market by End User
6.6.1 Market Overview
6.6.2 Pharmaceutical & Biotechnology Companies
6.6.3 Academic & Research Institutes
6.6.4 Others
6.7 Global Cell Therapy Manufacturing Market by Region
6.7.1 Market Overview
6.7.2 North America
6.7.3 Europe
6.7.4 Asia Pacific
6.7.5 Latin America
6.7.6 Middle East and Africa
7 North America Cell Therapy Manufacturing Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Cell Therapy Manufacturing Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Cell Therapy Manufacturing Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Cell Therapy Manufacturing Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Cell Therapy Manufacturing Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Funding Analysis
14.1 Analysis by Funding Instances
14.2 Analysis by Type of Funding
14.3 Analysis by Funding Amount
14.4 Analysis by Leading Players
14.5 Analysis by Leading Investors
14.6 Analysis by Geography
15 Partnership and Collaborations Analysis
15.1 Analysis by Partnership Instances
15.2 Analysis by Type of Partnership
15.3 Analysis by Leading Players
15.4 Analysis by Geography
16 Regulatory Framework
16.1 Regulatory Overview
16.1.1 US FDA
16.1.2 EU EMA
16.1.3 INDIA CDSCO
16.1.4 JAPAN PMDA
16.1.5 Others
17 Supplier Landscape
17.1 Novartis AG
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 F.Hoffmann La Roche AG
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Gilead Sciences, Inc.
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Thermo Fischer Scientific, Inc.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Catalent, Inc.
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 JSR Life Sciences LLC (KBI Biopharma Inc)
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Waisman Center (Waisman Biomanufacturing)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Cell and Gene Therapy Catapult
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Merck KGaA
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Lonza Group
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Oxford Biomedica Plc
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 WuXi AppTec
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Charles River Laboratories International Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Institut Merieux (ABL Inc.)
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certifications
17.15 BioCentriq
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
17.16 Centre for Commercialization of Regenerative Medicine (CCRM)
17.16.1 Financial Analysis
17.16.2 Product Portfolio
17.16.3 Demographic Reach and Achievements
17.16.4 Mergers and Acquisitions
17.16.5 Certifications
17.17 Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics)
17.17.1 Financial Analysis
17.17.2 Product Portfolio
17.17.3 Demographic Reach and Achievements
17.17.4 Mergers and Acquisitions
17.17.5 Certifications
17.18 Amgen Inc.
17.18.1 Financial Analysis
17.18.2 Product Portfolio
17.18.3 Demographic Reach and Achievements
17.18.4 Mergers and Acquisitions
17.18.5 Certifications
17.19 Bluebird Bio Inc.
17.19.1 Financial Analysis
17.19.2 Product Portfolio
17.19.3 Demographic Reach and Achievements
17.19.4 Mergers and Acquisitions
17.19.5 Certifications
17.20 Takeda Pharmaceutical Company Limited
17.20.1 Financial Analysis
17.20.2 Product Portfolio
17.20.3 Demographic Reach and Achievements
17.20.4 Mergers and Acquisitions
17.20.5 Certifications
18 Global Cell Therapy Manufacturing Market - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 4.24 billion in 2023, driven by the increasing prevalence of chronic diseases and technological advancement in cell therapies.
The market is anticipated to grow at a CAGR of 14.7% during the forecast period of 2024-2032 and reach a market value of USD 14.60 billion by 2032.
The increasing prevalence of chronic diseases and technological advancement in cell therapies are significantly driving the market growth.
The increasing popularity of CART-T cell in the market is a major trend which is bolstering the growth of the market.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is major regional market.
The types of cell therapy in the market include T-cell therapies, dendritic cell therapies, tumour cell therapies, and stem cell therapies, among others.
The source of cells in the market can be divided into autologous cells and allogeneic cell.
The different scale of operations in the market are preclinical, clinical, and commercial.
Cell therapy finds wide applications in oncology, cardiovascular diseases, and orthopaedic diseases, among others.
The technologies used in cell therapy manufacturing are somatic cell technology, cell immortalization technology, viral vector technology, genome editing technology, cell plasticity technology, and 3d technology, among others.
The end users in the market include pharmaceutical and biotechnology companies, academic and research institutes, among others.
Key players involved in the market are Novartis AG, F.Hoffmann La Roche AG, Gilead Sciences, Inc., Thermo Fischer Scientific, Inc., Catalent, Inc., JSR Life Sciences LLC (KBI Biopharma Inc), Waisman Center (Waisman Biomanufacturing), Cell and Gene Therapy Catapult, Merck KGaA, Lonza Group, Oxford Biomedica Plc., WuXi AppTec, Charles River Laboratories International Inc., Institut Merieux (ABL Inc.), BioCentriq, Centre for Commercialization of Regenerative Medicine (CCRM), Fujifilm Holdings Corporation (Fujifilm Cellular Dynamics), Amgen Inc., Bluebird Bio Inc., and Takeda Pharmaceutical Company Limited.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER